The global digital therapeutics (DTx) market size was valued at $6.2 billion in 2023 and is expected to expand at a compound annual growth rate of 27.2% from 2024 to 2030, according to Grand View Research. That growth is evident in the number of digital therapeutics products hitting the market. A Blue Matter Consulting whitepaper notes that in 2023, 154 prescription digital therapeutics were identified with U.S. market intentions – 15 more than the previous year’s 139.
Let’s look at the benefits of digital therapeutics and how DTx applies to injured workers and workers’ compensation medical care.
What Are Digital Therapeutics?
The Digital Therapeutics Alliance defines digital therapeutics as health software “intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient’s health.”
Not to be confused with apps that track fitness, encourage medication adherence, or monitor patient activity, DTx products deliver medical interventions directly to patients. They work in a variety of ways, from using virtual reality to delivering cognitive behavioral therapy, and are typically accessed through a smartphone or tablet.
Digital therapeutics differ from general digital health products in that they are evidence-based with studies or clinical trials that demonstrate some form of clinical value for a specific medical condition. They are held to the same standards of evidence and regulatory requirements as traditional medical treatments. Unlike your typical health or wellness app, digital therapeutics can earn U.S. Food and Drug Administration (FDA) approval to help treat certain illnesses and injuries.
Continue reading the article in full at the Healthesystems Blog.
